Precision Cardiovascular (PCV), an innovator in next-generation cardiac health solutions, today announced the appointment of Matthew I. Mace, B.Sc., AHCS-accredited Clinical Physiologist and seasoned medtech strategist, to its Board of Directors.

Matthew brings to Precision Cardiovascular critical expertise in clinical development, regulatory strategy, and quality systems as the Company prepares to transition from pre-clinical to clinical stages in early 2026.

Matthew has specialised experience over 15 years across invasive and non-invasive cardiovascular technologies:

• Implantables Leadership:

As former UK & Ireland Product Manager at Abbott, spearheaded the commercialisation efforts of Cardiac Resynchronisation Therapy (CRT) devices and launched the UK’s first CardioMEMS HF monitoring sites, contributing to a >5% market share gain in CRM devices

• Non-Invasive Innovation:

As Acorai’s Chief Scientific Officer and Co-Founder, led the team to achieve FDA Breakthrough designation for their ML-driven intracardiac pressure reader, securing over $17 million in funding and further initiated an unprecedented global trial involving 1,600 patients across six countries in record time, significantly outpacing traditional clinical trial timelines.

• Commercial Leadership:

Prior to joining Acorai, led global marketing and sales at Circle Cardiovascular Imaging (CVI), an innovative Canadian radiology SaaS company. During Matthew’s tenure, CVI more than doubled its revenue to over $50 million ARR in 18 months.

• Regulatory:

Matthew has a proven track record in regulatory pathways, including FDA TAP program access and EU CE-marking strategies, as well as establishing and working with quality systems for early-stage medtech firms and blue-chip organisations.

'Precision Cardiovascular stands at a key moment, bridging cutting-edge research with real-world clinical impact,' said Matthew Mace.

'Leveraging my experience in both implantable devices and AI-driven hemodynamic monitoring aligns perfectly with the Company’s mission to redefine cardiac care. I’m honoured to contribute to its journey toward clinical validation and global adoption.'

CEO Mohamed Abou-Alam emphasised the appointment’s significance:

'Matthew’s dual knowledge of traditional cardiac devices and ML-driven solutions accelerates our ability to navigate complex regulatory landscapes. Guidance from Matthew will be instrumental as we advance our pipeline into clinical trials next year, ensuring our innovations meet the highest standards of safety and efficacy.'

Matthew’s appointment coincides with Precision Cardiovascular’s other key funding and appointments due to be announced as it expands its pre-clinical work in minimally invasive hemodynamic monitoring. The Company aims to initiate first-in-human trials for its flagship sensor technology in 2026.

About Precision Cardiovascular

Precision Cardiovascular develops novel remote monitoring solutions for heart failure management. Its pipeline integrates advanced sensor technology with machine learning to enable reliable and proactive cardiac care in everyday settings. The Precision Cardiovascular system is not cleared for clinical use in any geography and is at present an investigational pre-clinical device.

Media Contact:

Precision Cardiovascular
The Magdi Yacoub Institute
Heart Science Centre, Harefield Hospital

info@precision-cv.com
+44 (0) 1895 760730